Accessibility Menu
C4 Therapeutics logo

C4 Therapeutics

(NASDAQ) CCCC

Current Price$3.71
Market Cap$407.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-86%
5 Year-91%
1 Year+69%
1 Month-6%
C4 Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 3.692026-07-17
C4 Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.11%USD 4.062026-07-10
1 month-5.87%USD 3.922026-06-17
3 month+26.37%USD 2.922026-04-17
Year to date+93.19%USD 1.912025-12-31
1 year+69.27%USD 2.182025-07-17
3 year+1.93%USD 3.622023-07-18
5 year-90.76%USD 39.952021-07-16
Since inception-85.52%USD 25.492020-10-02

C4 Therapeutics Financials at a Glance

Market Cap

$407.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$34.86M

Net Income (TTM)

-$103.80M

EPS (TTM)

-$1.18

P/E Ratio

-3.12

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Price

$3.71

Volume

92,185

Open

$3.47

Previous Close

$3.71

Daily Range

$3.45 - $3.77

52-Week Range

$1.69 - $5.17

Estimated Earnings Date

Aug 6, 2026

CCCC News

Two people participating in a telehealth session

Why C4 Therapeutics Stock Crushed the Market on Monday

Eric VolkmanSep 15, 2025
Foolcom-Featured.png

CCCC Revenue Drops 46%

Motley Fool Markets TeamAug 7, 2025

CCCC: Motley Fool Moneyball Superscore

57

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About C4 Therapeutics

C4 Therapeutics creates medicines that destroy harmful proteins. These treatments help patients with cancer and brain diseases. The drugs use the body's natural recycling system to work.

A Look at the Pipeline

  • Hematology Pipeline: Oral medicines like cemsidomide target proteins that cause blood cancers; currently in clinical trials for multiple myeloma.
  • Lung Cancer Therapies: Selective degraders designed to treat patients with specific mutations that resist existing lung cancer pills.
  • Neurological Programs: Early-stage drugs that cross the blood-brain barrier to treat diseases affecting the central nervous system.
  • Partnered Research: Joint projects that use the company's platform to discover treatments for various oncological and inflammatory conditions.

Growing the Partner List

  • Signed a supply agreement with Pfizer in September 2025 to study a combination treatment for multiple myeloma.
  • Started a discovery collaboration with Merck KGaA in March 2024 to identify two new cancer-fighting proteins.
  • Partnered with Betta Pharma in May 2023 to develop and sell lung cancer treatments in Greater China.
  • Expanded an existing relationship with Roche in 2023 to research new therapeutic targets for various indications.

What Makes the Tech Different?

C4 Therapeutics uses its TORPEDO platform to design small molecules that act like bridges between disease proteins and E3 ligases, which are the body's natural disposal agents. This method allows the company to eliminate entire proteins rather than just blocking them, which may lead to more effective and long-lasting results for patients.

Checking the Recent Numbers

  • Revenue hit $11 million in Q4 2025, up 112.8% year-over-year.
  • Net loss was $20.5 million in Q4 2025, which improved 40.7% compared to Q4 2024.
  • Operating income reached -$23.1 million in Q4 2025, an improvement of 38.6% from the previous year.
  • Free cash flow was -$22.2 million in Q4 2025, which worsened by 23.6% from Q4 2024.

Bottom Line

C4 Therapeutics has evolved from a research startup into a clinical-stage company with multiple drug candidates testing in human trials. Its growth is supported by a specialized protein-destruction platform and high-value partnerships with global pharmaceutical leaders.

AI Generated • May 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

104

CEO

Andrew J. Hirsch, MBA

Website

www.c4therapeutics.com

Headquarters

Watertown, MA 02472, US

CCCC Financials

Key Financial Metrics (TTM)

Gross Margin

94.83%

Operating Margin

-326.56%

Net Income Margin

-297.76%

Return on Equity

-50.68%

Return on Capital

-33.01%

Return on Assets

-31.56%

Earnings Yield

-32.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$407.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

110.57M

Volume

92.19K

Avg. Volume

3.18M

Financials (TTM)

Gross Profit

$33.06M

Operating Income

-$113.84M

EBITDA

-$100.38M

Operating Cash Flow

-$95.35M

Capital Expenditure

-$671.00K

Free Cash Flow

-$96.02M

Cash & ST Invst.

$235.67M

Total Debt

$58.45M

C4 Therapeutics Performance Analysis

C4 Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 31,096,000-32.1%
20232023-12-31USD 20,756,000-33.3%
20242024-12-31USD 35,584,00071.4%
20252025-12-31USD 35,947,0001.0%
C4 Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-10.7%
Q32025-09-3073.8%
Q42025-12-31-1.9%
Q12026-03-31-44.2%
C4 Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.6244.0%
20232023-12-31USD -2.671.7%
20242024-12-31USD -1.52-43.1%
20252025-12-31USD -1.27-16.6%
C4 Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-18.9%
Q42025-12-3159.1%
Q12026-03-31-11.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$6.15M

-15.0%

Gross Profit

$4.35M

-39.9%

Gross Margin

70.72%

N/A

Market Cap

$407.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.92M

N/A

Employees

104

N/A

Net Income

-$25.13M

+4.5%

EBITDA

-$23.33M

+9.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$235.67M

+9.6%

Total Debt

$58.45M

-9.2%

Accounts Receivable

$2.88M

-64.1%

Inventory

$0.00

N/A

Long Term Debt

$51.93M

-11.2%

Short Term Debt

$6.52M

+10.2%

Return on Assets

-31.56%

N/A

Return on Invested Capital

-37.74%

N/A

Free Cash Flow

-$30.01M

+9.8%

Operating Cash Flow

-$29.94M

+10.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OABIOmniAb, Inc.
$2.12+3.92%
CDXSCodexis, Inc.
$2.24+3.70%
PEPGPepGen Inc.
$2.25+0.00%
MOLNMolecular Partners AG
$3.90-4.88%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
PATHUiPath
$12.15+0.01%
JOBYJoby Aviation
$7.23-0.01%

Questions About CCCC

What is the current price of C4 Therapeutics?

C4 Therapeutics is trading at $3.71 per share.

What is the 52-week range for C4 Therapeutics?

Over the past 52 weeks, C4 Therapeutics has traded between $1.69 and $5.17.

How much debt does C4 Therapeutics have?

As of the most recent reporting period, C4 Therapeutics reported total debt of $58.45M.

How much cash does C4 Therapeutics have on hand?

C4 Therapeutics reported $61.27M in cash and cash equivalents in its most recent financial results.

What is C4 Therapeutics’s dividend yield?

C4 Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services